Core Viewpoint - New Hope (000876.SZ) reported a decrease in revenue and sales prices for its hog sales in August 2025, primarily due to changes in the domestic hog market conditions [1] Sales Performance - The company sold 1.3378 million hogs in August 2025, representing a month-on-month increase of 2.71% and a year-on-year increase of 4.72% [1] - Revenue from hog sales was 1.722 billion yuan, showing a month-on-month decrease of 4.45% and a year-on-year decrease of 30.73% [1] Pricing Trends - The average selling price of hogs was 13.54 yuan per kilogram, with a month-on-month decrease of 6.23% and a year-on-year decrease of 32.74% [1] - The significant year-on-year decline in selling prices was mainly influenced by fluctuations in the domestic hog market [1]

Core Viewpoint - Multiple myeloma, the second most common hematological malignancy, poses significant treatment challenges due to its incurable nature and high relapse rates, but advancements in medical technology have led to innovative therapies that offer hope for "functional cure" and improved quality of life for patients [1][8]. Group 1: Disease Overview - Multiple myeloma is characterized by malignant proliferation of plasma cells, which are crucial for immune function, leading to the production of ineffective immunoglobulins that harm normal bodily functions [3][4]. - The disease's early symptoms are often non-specific, leading to misdiagnosis, with common symptoms summarized by the "CRAB" acronym: hypercalcemia, renal impairment, anemia, and bone lesions [3][4]. Group 2: Diagnosis and Monitoring - Patients often seek treatment for symptoms like renal issues or bone pain, mistakenly attributing them to other conditions, which can delay diagnosis and worsen outcomes [4][5]. - Monitoring serum protein levels is critical, with levels exceeding 50 g/L warranting further investigation for multiple myeloma [4]. Group 3: Treatment Approaches - Treatment for multiple myeloma is individualized, with options including traditional chemotherapy, targeted therapy, immunotherapy, and stem cell transplantation, depending on patient-specific factors [7][9]. - Recent advancements have introduced bispecific antibodies as a standard treatment for relapsed/refractory multiple myeloma, showing efficacy rates over 60% and complete response rates around 35% [9]. Group 4: Prognosis and Future Directions - The five-year survival rate for multiple myeloma patients has improved significantly, with many now living for over a decade, thanks to new therapies [8][9]. - The concept of "functional cure" is emerging, where patients may have residual tumor cells that are undetectable and coexist with the immune system, allowing for a normal quality of life [9].

证券代码：000876 证券简称：新希望 公告编号：2025-96 债券代码：127015、127049 债券简称：希望转债、希望转 2 新希望六和股份有限公司 2025 年 8 月生猪销售情况简报 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 新希望六和股份有限公司（以下简称"公司"）下属子公司从事 生猪养殖业务。按照《深圳证券交易所上市公司自律监管指引第 3 号 ——行业信息披露》规定，深交所鼓励从事畜禽、水产养殖业务的上 市公司每月通过临时公告形式披露相关业务销售情况，公司将参照指 引相关规定执行。 一、2025 年 8 月份生猪销售情况 公司 2025 年 8 月销售生猪 133.78 万头，环比变动 2.71%，同比 变动 4.72%。收入 17.22 亿元，环比变动-4.45%，同比变动-30.73%， 同比降幅较大的原因是销售价格同比下降。商品猪销售均价 13.54 元 /公斤，环比变动-6.23%，同比变动-32.74%，销售价格同比降幅较大 主要是受国内生猪市场行情变化的影响。 | 月份 | | 生猪销售数量 | | | 生猪销售收入 | ...

Group 1 - The core point of the article is that New Hope (000876.SZ) reported its sales figures for August 2025, indicating a total of 1.3378 million pigs sold, which represents a month-on-month increase of 2.71% and a year-on-year increase of 4.72% [2] - The revenue generated from these sales amounted to 1.722 billion yuan, showing a month-on-month decrease of 4.45% and a year-on-year decrease of 30.73% [2] - The significant year-on-year decline in revenue is attributed to a decrease in sales prices compared to the previous year [2]

Core Viewpoint - New Hope reported an increase in pig sales volume for August 2025, but a significant decline in revenue due to lower sales prices [1] Group 1: Sales Performance - The company sold 1.3378 million pigs in August 2025, representing a month-on-month increase of 2.71% and a year-on-year increase of 4.72% [1] Group 2: Revenue Analysis - The revenue for August 2025 was 1.722 billion yuan, which reflects a month-on-month decrease of 4.45% and a year-on-year decrease of 30.73% [1] - The substantial year-on-year revenue decline is attributed to a decrease in sales prices [1]

Core Insights - New Hope (000876.SZ) reported a total of 1.3378 million pigs sold in August 2025, reflecting a month-on-month increase of 2.71% and a year-on-year increase of 4.72% [1] - The company's revenue for the same period was 1.722 billion yuan, showing a month-on-month decrease of 4.45% and a year-on-year decrease of 30.73%, primarily due to a decline in sales prices [1] - The average selling price of commercial pigs was 13.54 yuan per kilogram, with a month-on-month decrease of 6.23% and a year-on-year decrease of 32.74%, largely influenced by changes in the domestic pig market [1]

Core Viewpoint - New Hope (000876.SZ) reported a decrease in revenue and sales prices for its hog sales in August 2025, primarily due to changes in the domestic hog market conditions [1] Sales Performance - The company sold 1.3378 million hogs in August 2025, representing a month-on-month increase of 2.71% and a year-on-year increase of 4.72% [1] - Revenue from hog sales was 1.722 billion yuan, showing a month-on-month decrease of 4.45% and a year-on-year decrease of 30.73% [1] Pricing Trends - The average selling price of hogs was 13.54 yuan per kilogram, with a month-on-month decrease of 6.23% and a year-on-year decrease of 32.74% [1] - The significant year-on-year decline in selling prices was mainly influenced by fluctuations in the domestic hog market [1]

Core Viewpoint - The company has approved the temporary use of idle raised funds to supplement working capital, amounting to no more than RMB 110 million, for a period not exceeding 12 months, ensuring compliance with relevant regulations and maintaining the integrity of the original fundraising purpose [3][4][18]. Group 1: Board Meeting - The company's 10th Board of Directors held its 6th meeting on September 4, 2025, via telecommunication, with all 9 directors participating, confirming the legality and validity of the resolutions made [2][3]. - The board unanimously approved the proposal to use part of the idle raised funds to temporarily supplement working capital, with a vote of 9 in favor, 0 against, and 0 abstentions [3][4]. Group 2: Fundraising and Usage - The company raised a total of RMB 3,999,999,988.44 through a non-public offering of up to 177,147,918 shares, with a net amount of RMB 3,994,750,464.69 after deducting issuance costs [3][14]. - As of June 30, 2025, the company plans to use up to RMB 110 million of idle raised funds to improve efficiency and reduce financial costs, with the condition that it will not affect the progress of the original investment projects [4][16][19]. Group 3: Supervisory Approval - The 10th Supervisory Board also held its 6th meeting on September 4, 2025, with all 3 supervisors participating, confirming the legality of the resolutions [7][8]. - The Supervisory Board agreed with the proposal to use idle raised funds for working capital, emphasizing that it aligns with the company's development needs and does not violate any laws or regulations [8][20]. Group 4: Financial Implications - The use of idle funds is expected to save approximately RMB 1.65 million in financial costs, as it reduces the need for bank loans [19]. - The company commits to returning the funds to the dedicated account based on the progress of the investment projects, ensuring that the original fundraising purpose remains intact [19][21].

证券日报网讯 9月4日晚间，新希望发布公告称，公司第十届监事会第六次会议审议通过了《关于使用 部分闲置募集资金临时补充流动资金的议案》。 （文章来源：证券日报） ...

证券日报网讯 9月4日晚间，新希望发布公告称，公司第十届董事会第六次会议审议通过了《关于使用 部分闲置募集资金临时补充流动资金的议案》。 （文章来源：证券日报） ...